Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Net Income (2020 - 2025)

Maxcyte (MXCT) has disclosed Net Income for 6 consecutive years, with -$12.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income fell 7.43% to -$12.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$45.6 million, a 27.69% decrease, with the full-year FY2024 number at -$41.1 million, down 8.26% from a year prior.
  • Net Income was -$12.4 million for Q3 2025 at Maxcyte, roughly flat from -$12.4 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$2.7 million in Q3 2021 to a low of -$12.4 million in Q3 2025.
  • A 5-year average of -$8.2 million and a median of -$9.4 million in 2024 define the central range for Net Income.
  • Peak YoY movement for Net Income: surged 42.76% in 2022, then crashed 167.55% in 2023.
  • Maxcyte's Net Income stood at -$4.9 million in 2021, then increased by 1.33% to -$4.8 million in 2022, then decreased by 9.74% to -$5.3 million in 2023, then plummeted by 100.78% to -$10.6 million in 2024, then dropped by 17.17% to -$12.4 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Net Income are -$12.4 million (Q3 2025), -$12.4 million (Q2 2025), and -$10.3 million (Q1 2025).